Cost-utility analysis of erenumab preventive treatment for chronic migraine in China. (PubMed, Front Public Health) - Oct 7, 2026 - "Threshold price analysis showed that erenumab would need to decrease to CNY 141.82 and CNY 386.81 per 70-mg box to be cost-effective at WTP thresholds of 1× and 3× GDP per capita, respectively. From the Chinese health system perspective, erenumab as preventive treatment provides modest health gains for adults with chronic migraine but is unlikely to be cost-effective at its current price."
HEOR • Journal • CNS Disorders • Migraine • Pain
|
|
Lijiang Wang; Menglu Zhu; Miaolian Wu; Qingqing Hu; Shengying Lou; Zhengqiang Hu
|